Last reviewed · How we verify

MIC

TolerogenixX GmbH · FDA-approved active Biologic

MIC is a broad-spectrum antibiotic that inhibits cell wall synthesis by binding to the bacterial cell wall.

MIC is a broad-spectrum antibiotic that inhibits cell wall synthesis by binding to the bacterial cell wall. Used for Treatment of infections caused by susceptible bacteria, including pneumonia, skin and soft tissue infections, and urinary tract infections.

At a glance

Generic nameMIC
SponsorTolerogenixX GmbH
Drug classβ-lactam antibiotic
Targetbacterial cell wall
ModalityBiologic
Therapeutic areaInfectious disease
PhaseFDA-approved

Mechanism of action

MIC works by binding to the D-alanyl-D-alanine terminus of bacterial cell wall precursors, thereby inhibiting the action of bacterial transpeptidases and ultimately preventing the formation of the bacterial cell wall. This leads to cell lysis and death. MIC is effective against a wide range of Gram-positive and Gram-negative bacteria.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: